Faculty profile

Lee-Hwa Tai

ResearcherImmunologyUniversité de Sherbrooke

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Sherbrooke directory, so their courses may be missing. Find their university profile.

Lee-Hwa Tai

Researcher

Immunology

Health Sciences

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
21 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (5 CIHR, 1 NSERC), most recently in 2024.
Supervisor on 2 trainee awards (2 CIHR), most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

134

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Immunotherapy Translational Research Immune Suppression Metastasis Triple Negative Breast Cancer Immunomodulation Tumor Immune Microenvironment Virotherapy

Latest papers

The Acute Response of Cytotoxic T Cells Following Work-Matched Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy : a Pilot Study.
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2026
Reprogramming the tumor microenvironment to boost adoptive T cell therapy.
Frontiers in immunology · 2025 · senior author
Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models.
Molecular therapy. Oncology · 2025 · senior author

All 26 publications

Latest funding

Using the body's blood immune cells to fight triple negative breast cancer
CIHR · 2026 · Supervisor
$140,000
Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus
CIHR · 2025 · Co-investigator
$1,139,850
Precision virotherapy to treat bladder cancer
CIHR · 2024 · Nominated PI
$814,726

All 11 grants and awards

26 publications.

The Acute Response of Cytotoxic T Cells Following Work-Matched Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy : a Pilot Study.

Parent-Roberge H, Fontvieille A, Poirier L, Tai LH, Pavic M, Fulop T, Riesco E

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme2026

DOI: 10.1139/apnm-2025-0157 PMID: 42647954

Reprogramming the tumor microenvironment to boost adoptive T cell therapy.

Meza Pacheco MF, Tai LH

Frontiers in immunology2025Senior author

DOI: 10.3389/fimmu.2025.1677548 PMID: 41208982

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models.

Daniel L, Ndiaye KS, Giguère H, Custeau LJ, Léger JL, St-Cyr G, Ndongo NE, Richard PO, Tai LH

Molecular therapy. Oncology2025Senior author

DOI: 10.1016/j.omton.2025.201016 PMID: 40687438

Nanofilament immunotherapy induces potent antitumor vaccine responses.

Neil K, Génier S, Poisson MÈ, Douchin J, Giguère H, Daniel L, Gonzalez MF, Huang S, Trinh VQ, Tai LH, Rodrigue S, Millau JF

Journal for immunotherapy of cancer2025

DOI: 10.1136/jitc-2024-011331 PMID: 40889802

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T

Nature biomedical engineering2025

DOI: 10.1038/s41551-024-01259-7 PMID: 39609558

Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models.

St-Cyr G, Daniel L, Giguère H, Birtch R, Ilkow CS, Tai LH

Scientific reports2025Senior author

DOI: 10.1038/s41598-025-01584-0 PMID: 40360587

Toll-like receptor 4 inhibition sensitizes non-small cell lung cancer to radiotherapy.

Haroun R, Rutihinda C, Diallo AH, Ordonez JP, Nassri S, Shams A, Pacheco MFM, Saidi NE, Bouchard L, Turgeon GA, Gris D, Tai LH, Oweida AJ

Cancer biology & therapy2025

DOI: 10.1080/15384047.2025.2590881 PMID: 41332426

Acute natural killer cells response to a continuous moderate intensity and a work-matched high intensity interval exercise session in metastatic cancer patients treated with chemotherapy.

Parent-Roberge H, Fontvieille A, Poirier L, Tai LH, Pavic M, Fülöp T, Riesco E

Brain, behavior, & immunity - health2024

DOI: 10.1016/j.bbih.2024.100825 PMID: 39155952

Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines.

Amhis N, Carignan J, Tai LH

Molecular therapy. Oncology2024Senior author

DOI: 10.1016/j.omton.2024.200825 PMID: 39006944

2023 Canadian Surgery Forum

Brière R, Habashi R, Merchant S, Cadili L, Alhumoud Z, Lau R, Gawad N, Valji R, Balmes PN, Tan JGK

Canadian Journal of Surgery20231 citationsOpen Access

DOI: 10.1503/cjs.014223 PMID: W4389488805

Using the body's blood immune cells to fight triple negative breast cancer

SupervisorCIHR2026Fellowship: Canada Impact+ Research Training Awards - Postdoctoral

Principal investigators: Goradel, Nasser Hashemi

Keywords: Immunotherapy; Patient Derived Organoids; Triple Negative Breast Cancer; Tumor Inflitrating Lumphocytes

$140,000

Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus

Co-investigatorCIHR2025Project Grant

Principal investigators: Azad, Taha

Keywords: Cancer; Cancer Immunotherapy; Oncolytic Viruses; Synthetic Biology

$1,139,850

Precision virotherapy to treat bladder cancer

Nominated PICIHR2024Project Grant

Principal investigators: Tai, Lee-Hwa

Keywords: Bcg Failure; Bladder Cancer; Bladder-Sparing Therapy; Cytokines; Immunomodulation; Immunotherapy; Mouse Models; Translational Research; Tumor Immune Microenvironment; Virotherapy

$814,726

Harnessing blood-derived immune cells to overcome challenges in TIL therapy

Nominated PICIHR2024Project Grant

Principal investigators: Tai, Lee-Hwa

Keywords: Immune Suppression; Immunomodulation; Immunotherapy; Metastasis; Organoids; Poor Prognosis Cancers; Translational Research; Triple Negative Breast Cancer; Tumor Immune Microenvironment; Virotherapy

$1,009,800

Effet aigu de l'exercice aérobie personnalisé sur la réponse immunitaire anticancer chez des individus en cours de traitement pour un cancer curable

SupervisorCIHR2024Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Poirier, Laurence

Keywords: Cancer; Cellules Cytotoxiques; Exercice; Migration Des Cellules Immunitaires; Mobilisation Des Cellules Immunitaires; Traitement Anticancer

$120,000

Bioengineering viruses to create safer and more effective oncolytic viruses

Co-investigatorCIHR2023Project Grant

Principal investigators: Azad, Taha

Keywords: Cancer Immunotherapy; Cancer, Genome Editing; Crispr/Cas9; Immunotherapy; Next Generation Sequencing; Oncolytic Viruses; Screening; Synthetic Biology; Vaccines

$986,850

Preclinical multilaboratory studies for cancer immunotherapy

Nominated PICIHR2023Planning and Dissemination Grant - Institute Community Support

Principal investigators: Tai, Lee-Hwa; Bell, John C; Lalu, Manoj M

Keywords: Cancer Immunotherapy; Chimeric Antigen Receptor T Cell Therapy; Experimental Rigour; Multilaboratory Study; Natural Killer Cell Therapy; Oncolytic Virus Therapy; Translation; Tumour Infiltrating Lymphocyte Therapy

$10,000

Chronic Inflammation, Immunity and Cancer 2019

Co-investigatorCIHR2019Planning and Dissemination Grant - Institute Community Support

Principal investigators: Boudreau, François

Keywords: Biological Models; Digestive Cancer; Immunotherapy; Inflammatory Bowel Diseases; Mechanisms Of Inflammation; Microbiome

$15,000

Targeting metastatic disease of triple negative breast cancer with an immunogenic cancer vaccine

Nominated PICIHR2018Project Grant

Principal investigators: Tai, Lee-Hwa

Keywords: Autologous Whole Tumor Cell Vaccines; Cancer Immunotherapy; Immune Suppression; Innate And Adaptive Immunity; Metastasis; Oncolytic Virus; Poor Prognosis; Postoperative Vaccination; Translational Research; Triple Negative Breast Cancer

$703,800

Cellular energetics in natural killer cell development and function

Principal investigatorNSERC2017Discovery Grants Program - Individual

Principal investigators: Tai, LeeHwa

$182,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Lee-Hwa Tai

Research

Latest papers

Latest funding

The Acute Response of Cytotoxic T Cells Following Work-Matched Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy : a Pilot Study.

Reprogramming the tumor microenvironment to boost adoptive T cell therapy.

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models.

Nanofilament immunotherapy induces potent antitumor vaccine responses.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models.

Toll-like receptor 4 inhibition sensitizes non-small cell lung cancer to radiotherapy.

Acute natural killer cells response to a continuous moderate intensity and a work-matched high intensity interval exercise session in metastatic cancer patients treated with chemotherapy.

Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines.

2023 Canadian Surgery Forum

Cellular energetics in natural killer cell development and function

Frequent collaborators

Tommy Alain

Taha Azad

Abolfazl Nik-Akhtar

Dean Fergusson

Harminder Singh

Vickie Baracos

Peter Greer

Michele Ardolino

David Evans

Daniel McIsaac

Kazuhiro Yasufuku

Michael Reedijk

Guillaume Martel

Liane Feldman

Madhuri Koti

Jason Sutherland

Julie Hallet

Daniel McIsaac

Eitan Prisman

Melanie Tsang

Wojtek Wiercioch

Marko Simunovic

Philip Devereaux

Mohit Bhandari

Sameer Parpia

Joanna Dionne

Cagla Eskicioglu

Bradley Allan Petrisor

Timothy Whelan

Edward Passos

John Agzarian

Paul Engels

Ilun Yang

Dennis Hong

Bobby Shayegan

Mark Norman Levine

Jean-Simon Diallo

Girish Kulkarni

Natalie Coburn

Dean Fergusson